Related Experiment Video

Updated: Jun 15, 2026

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
06:52

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

Atherosclerosis in the evolution of Alzheimer's disease: can treatment reduce cognitive decline?

Simona Luzzi1, Lucia Vella, Marco Bartolini

  • 1Department of Neuroscience, Marche Polytechnic University, Ancona, Italy.

Journal of Alzheimer'S Disease : JAD
|February 26, 2010
PubMed

Insights

Cerebrovascular impairment and Alzheimer's disease (AD) interact. Atherosclerosis, hypertension, and dyslipidemia influence AD progression, with potential benefits from related drug therapies.

Area of Science:

  • Neurology
  • Vascular Medicine
  • Gerontology

Background:

  • The link between cerebrovascular issues and Alzheimer's disease (AD) is debated.
  • Atherosclerosis and its risk factors are implicated in dementia development.

Purpose of the Study:

  • To explore the interplay between degenerative and vascular mechanisms in dementia pathogenesis.
  • To examine the impact of hypertension and dyslipidemia on AD progression.

Main Methods:

  • Review of current evidence on cerebrovascular impairment and AD.
  • Analysis of data concerning hypertension, dyslipidemia, and AD evolution.
  • Discussion of pharmacological interventions for cognitive impairment.

Main Results:

  • Evidence suggests interaction between vascular and degenerative pathways in AD.
  • Hypertension and dyslipidemia significantly affect Alzheimer's disease progression.
  • Antihypertensive and lipid-lowering drugs may impact cognitive decline.

Conclusions:

  • Vascular factors, including atherosclerosis, hypertension, and dyslipidemia, play a crucial role in Alzheimer's disease.
  • Targeting vascular risk factors may offer therapeutic strategies for dementia.

More Related Videos

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons06:23

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons

Published on: October 30, 2018

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...